Differential role of glucocorticoid receptor based on its cell type specific expression on tumor cells and infiltrating lymphocytes
CONCLUSION: This study underscores the cell type-specific role of GR, where its expression on tumor cells is associated with aggressive features like EMT, while in infiltrating lymphocytes, it predicts a better prognosis, particularly within TNBC tumors. The GRsig emerges as a promising independent prognostic indicator across diverse BC subtypes.PMID:38643748 | DOI:10.1016/j.tranon.2024.101957 (Source: Translational Oncology)
Source: Translational Oncology - April 21, 2024 Category: Cancer & Oncology Authors: V P Snijesh Vidya P Nimbalkar Sharada Patil Savitha Rajarajan C E Anupama S Mahalakshmi Annie Alexander Ramu Soundharya Rakesh Ramesh B S Srinath Mohit Kumar Jolly Jyothi S Prabhu Source Type: research
Aurora kinase A inhibition plus Tumor Treating Fields suppress glioma cell proliferation in a cilium-independent manner
Transl Oncol. 2024 Apr 18;45:101956. doi: 10.1016/j.tranon.2024.101956. Online ahead of print.ABSTRACTTumor Treating Fields (TTFields) extend the survival of glioblastoma (GBM) patients by interfering with a broad range of tumor cellular processes. Among these, TTFields disrupt primary cilia stability on GBM cells. Here we asked if concomitant treatment of TTFields with other agents that interfere with GBM ciliogenesis further suppress GBM cell proliferation in vitro. Aurora kinase A (AURKA) promotes both cilia disassembly and GBM growth. Inhibitors of AURKA, such as Alisertib, inhibit cilia disassembly and increase ciliar...
Source: Translational Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Jia Tian Julianne C Mallinger Ping Shi Dahao Ling Loic P Deleyrolle Min Lin Habibeh Khoshbouei Matthew R Sarkisian Source Type: research
High expression of SLC27A2 predicts unfavorable prognosis and promotes inhibitory immune infiltration in acute lymphoblastic leukemia
In conclusion, SLC27A2 plays a vital role in the development of ALL.PMID:38640787 | DOI:10.1016/j.tranon.2024.101952 (Source: Translational Oncology)
Source: Translational Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Lihua Lu Jiazheng Li Yongzhi Zheng Luting Luo Yan Huang Jianda Hu Yanxin Chen Source Type: research
CREB3 facilitates Donafenib resistance in hepatocellular carcinoma cells via the LSD1/CoREST/p65 axis by transcriptionally activating long noncoding RNA ZFAS1
CONCLUSION: CREB3 overexpression contributed to Donafenib resistance in HCC cells by activating the ZFAS1/p65 axis.PMID:38641372 | DOI:10.1016/j.tranon.2023.101684 (Source: Translational Oncology)
Source: Translational Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Xunbo Hou Qiannan Xu Ruibao Liu Source Type: research
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome na ïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al
Transl Oncol. 2024 Jun;44:101820. doi: 10.1016/j.tranon.2023.101820. Epub 2023 Nov 15.NO ABSTRACTPMID:38641373 | DOI:10.1016/j.tranon.2023.101820 (Source: Translational Oncology)
Source: Translational Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Tobias Kiesslich Christian Mayr Dino Bekric Daniel Neureiter Source Type: research
Corrigendum to Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture
Transl Oncol. 2024 Jun;44:101927. doi: 10.1016/j.tranon.2024.101927. Epub 2024 Mar 8.NO ABSTRACTPMID:38641374 | DOI:10.1016/j.tranon.2024.101927 (Source: Translational Oncology)
Source: Translational Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Joseph Zenga Musaddiq Awan Anne Frei Jamie Foeckler Rachel Kuehn Oscar Villareal Espinosa Jennifer Bruening Becky Massey Stuart Wong Aditya Shreenivas Monica Shukla Julia Kasprzak Yunguang Sun Md Shaheduzzaman Fanghong Chen Tyce Kearl Heather A Himburg Source Type: research
LOX rises as a potential survival biomarker: A commentary on "Identification of LOX as a candidate prognostic biomarker in Glioblastoma multiforme" by Liu et al
Transl Oncol. 2024 Jun;44:101777. doi: 10.1016/j.tranon.2023.101777. Epub 2023 Sep 2.NO ABSTRACTPMID:38641375 | DOI:10.1016/j.tranon.2023.101777 (Source: Translational Oncology)
Source: Translational Oncology - April 19, 2024 Category: Cancer & Oncology Authors: Eduardo Silva-Pavez Hery Urra Source Type: research
Synergistic anticancer effects of doxorubicin and metformin combination therapy: A systematic review
CONCLUSION: The findings of this study show that the combined treatment regimen including doxorubicin and metformin has significant promise in fighting cancer. The observed synergistic effects suggest that this combination therapy could be valuable, in a setting. This study highlights the need for clinical research to validate and enhance the application of the doxorubicin metformin regimen.PMID:38636389 | DOI:10.1016/j.tranon.2024.101946 (Source: Translational Oncology)
Source: Translational Oncology - April 18, 2024 Category: Cancer & Oncology Authors: Fereshtehsadat Jalali Fatemeh Fakhari Afrah Sepehr Jaber Zafari Behnam Omidi Sarajar Pouria Sarihi Emad Jafarzadeh Source Type: research
A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma
In conclusion, this study highlights a novel co-targeting strategy using miR-105-5p mimics, MALAT-1, CCAT-1 and H19 siRNAs to efficiently hampers the immune checkpoints; PD-L1/PD-1 and CD155/TIGIT immune evasion properties in HCC.PMID:38631259 | DOI:10.1016/j.tranon.2024.101961 (Source: Translational Oncology)
Source: Translational Oncology - April 17, 2024 Category: Cancer & Oncology Authors: Reem A Assal Noha M Elemam Radwa Y Mekky Abdelrahman A Attia Aya Hesham Soliman Asmaa Ibrahim Gomaa Eleni K Efthimiadou Maria Braoudaki Sherif Ashraf Fahmy Rana A Youness Source Type: research
A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma
In conclusion, this study highlights a novel co-targeting strategy using miR-105-5p mimics, MALAT-1, CCAT-1 and H19 siRNAs to efficiently hampers the immune checkpoints; PD-L1/PD-1 and CD155/TIGIT immune evasion properties in HCC.PMID:38631259 | DOI:10.1016/j.tranon.2024.101961 (Source: Translational Oncology)
Source: Translational Oncology - April 17, 2024 Category: Cancer & Oncology Authors: Reem A Assal Noha M Elemam Radwa Y Mekky Abdelrahman A Attia Aya Hesham Soliman Asmaa Ibrahim Gomaa Eleni K Efthimiadou Maria Braoudaki Sherif Ashraf Fahmy Rana A Youness Source Type: research
Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial
Transl Oncol. 2024 Apr 14;45:101959. doi: 10.1016/j.tranon.2024.101959. Online ahead of print.ABSTRACTThe SWOG S1801 trial investigated the role of pembrolizumab, an anti-PD1 immune checkpoint inhibitor, in the perioperative setting of stage III or IV melanoma. This phase 2 trial compared two groups: one receiving pembrolizumab both before and after surgery (neoadjuvant-adjuvant), and another receiving it only post-surgery (adjuvant-only), with event-free survival (EFS) as the primary endpoint. Neoadjuvant strategies, involving pre-surgical drug administration, potentially offer rapid tumor control and a unique opportunity...
Source: Translational Oncology - April 15, 2024 Category: Cancer & Oncology Authors: Timoth ée Olivier Vinay Prasad Source Type: research
Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial
Transl Oncol. 2024 Apr 14;45:101959. doi: 10.1016/j.tranon.2024.101959. Online ahead of print.ABSTRACTThe SWOG S1801 trial investigated the role of pembrolizumab, an anti-PD1 immune checkpoint inhibitor, in the perioperative setting of stage III or IV melanoma. This phase 2 trial compared two groups: one receiving pembrolizumab both before and after surgery (neoadjuvant-adjuvant), and another receiving it only post-surgery (adjuvant-only), with event-free survival (EFS) as the primary endpoint. Neoadjuvant strategies, involving pre-surgical drug administration, potentially offer rapid tumor control and a unique opportunity...
Source: Translational Oncology - April 15, 2024 Category: Cancer & Oncology Authors: Timoth ée Olivier Vinay Prasad Source Type: research
Diagnostic and predictive significance of the ferroptosis-related gene TXNIP in lung adenocarcinoma stem cells based on multi-omics
CONCLUSION: The investigation conducted in this study systematically delved into the role of the ferroptosis-related gene TXNIP in Lung CSCs. The identification of TXNIP as a potentially valuable biomarker in this context could have significant implications for refining prognostic assessments and optimizing therapeutic strategies for advanced lung cancer.PMID:38615437 | DOI:10.1016/j.tranon.2024.101926 (Source: Translational Oncology)
Source: Translational Oncology - April 14, 2024 Category: Cancer & Oncology Authors: Yuanyuan Zheng Wei Yang Weixuan Wu Feng Jin Dehua Lu Jing Gao Shubin Wang Source Type: research
Diagnostic and predictive significance of the ferroptosis-related gene TXNIP in lung adenocarcinoma stem cells based on multi-omics
CONCLUSION: The investigation conducted in this study systematically delved into the role of the ferroptosis-related gene TXNIP in Lung CSCs. The identification of TXNIP as a potentially valuable biomarker in this context could have significant implications for refining prognostic assessments and optimizing therapeutic strategies for advanced lung cancer.PMID:38615437 | DOI:10.1016/j.tranon.2024.101926 (Source: Translational Oncology)
Source: Translational Oncology - April 14, 2024 Category: Cancer & Oncology Authors: Yuanyuan Zheng Wei Yang Weixuan Wu Feng Jin Dehua Lu Jing Gao Shubin Wang Source Type: research
Identification of clinically relevant subsets CD39 < sup > + < /sup > PD-1 < sup > + < /sup > CD8 < sup > + < /sup > T cells and CD39 < sup > + < /sup > regulatory T cells in intrahepatic cholangiocarcinoma using single-cell CyTOF
This study utilized mass cytometry by time of flight (CyTOF) to comprehensively analyze immune cell populations in fresh iCCA tumor samples and adjacent peritumor liver tissues. Notably, NK cell percentages significantly decreased in iCCA lesions compared to peritumor liver tissues. Conversely, an enrichment of immunosuppressive CD39+Foxp3+CD4+ regulatory T cells (CD39+T-regs) and exhausted-like CD8+T cells (with pronounced CD39 and PD-1 expression) within TIME was identified and confirmed by multiplex immunofluorescence staining in an independent patient cohort (n = 140). Crucially, tumor-infiltrating CD39+T-regs and CD39...
Source: Translational Oncology - April 12, 2024 Category: Cancer & Oncology Authors: Qi-Wei Zhang Meng-Xuan Zhu Wen-Feng Liu Wei-Wei Rui Yong Chen Xiao-Yi Ding Yong-Sheng Jiang Zhi-Yuan Wu Bin-Bin Liu Source Type: research
